{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:38:04Z","timestamp":1789580284019,"version":"build-2803163510"},"reference-count":19,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2018,2,22]],"date-time":"2018-02-22T00:00:00Z","timestamp":1519257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100007705","name":"Astellas Pharma Global Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007705","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Basic Clin Pharma Tox"],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The purpose of this study was to estimate the incidence rate (<jats:styled-content style=\"fixed-case\">IR<\/jats:styled-content>) of 10 common cancers in new users of antimuscarinic overactive bladder (<jats:styled-content style=\"fixed-case\">OAB<\/jats:styled-content>) medications. We conducted a cohort study using data recorded in Danish registers for patients newly exposed to the <jats:styled-content style=\"fixed-case\">OAB<\/jats:styled-content> drugs, darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine or trospium in years 2004\u20132012, aged \u226518\u00a0years and without cancer before treatment initiation. We estimated <jats:styled-content style=\"fixed-case\">IR<\/jats:styled-content>s for each study cancer (bladder, breast, colorectal, lung, melanoma, non\u2010Hodgkin lymphoma, pancreas, prostate, renal and uterine), standardised by age and sex and explored <jats:styled-content style=\"fixed-case\">IR<\/jats:styled-content> trends over time since treatment initiation. For all cancer analyses, only the first incident targeted cancer was considered. Of 72,917 patients (60% women; mean age at treatment start: 66\u00a0years), 3475 developed a study cancer during 259,072 person\u2010years of follow\u2010up. The most common study cancers were prostate (48.1% of study cancers in men), breast (40.0% of study cancers in women) and lung (15.4% of all study cancers). The overall standardised study cancer <jats:styled-content style=\"fixed-case\">IR<\/jats:styled-content> was 5.4 per 1000 person\u2010years (95% confidence interval, 5.3\u20135.6); <jats:styled-content style=\"fixed-case\">IR<\/jats:styled-content>s were similar across individual <jats:styled-content style=\"fixed-case\">OAB<\/jats:styled-content> drugs. The standardised <jats:styled-content style=\"fixed-case\">IR<\/jats:styled-content>s for bladder and prostate cancers, which have symptoms in common with <jats:styled-content style=\"fixed-case\">OAB<\/jats:styled-content>, were highest in the first 6\u00a0months of treatment initiation and lower thereafter. In contrast, <jats:styled-content style=\"fixed-case\">IR<\/jats:styled-content>s for other study cancers were nearly constant during follow\u2010up. Cancer <jats:styled-content style=\"fixed-case\">IR<\/jats:styled-content>s did not vary substantially by individual <jats:styled-content style=\"fixed-case\">OAB<\/jats:styled-content> drug. Protopathic bias is a plausible explanation for the higher rates of bladder and prostate cancers observed soon after starting <jats:styled-content style=\"fixed-case\">OAB<\/jats:styled-content> drug treatment.<\/jats:p>","DOI":"10.1111\/bcpt.12965","type":"journal-article","created":{"date-parts":[[2018,1,18]],"date-time":"2018-01-18T01:52:41Z","timestamp":1516240361000},"page":"612-619","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Incidence of Common Cancers in Users of Antimuscarinic Medications for Overactive Bladder: A Danish Nationwide Cohort Study"],"prefix":"10.1111","volume":"122","author":[{"given":"Jesper","family":"Hallas","sequence":"first","affiliation":[{"name":"University of Southern Denmark Odense C Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea V.","family":"Margulis","sequence":"additional","affiliation":[{"name":"RTI Health Solutions Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Potteg\u00e5rd","sequence":"additional","affiliation":[{"name":"University of Southern Denmark Odense C Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina S.","family":"Kristiansen","sequence":"additional","affiliation":[{"name":"University of Southern Denmark Odense C Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem J.","family":"Atsma","sequence":"additional","affiliation":[{"name":"Astellas Pharma B.V. Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwame","family":"Appenteng","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development, Inc. Northbrook IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"de Vogel","sequence":"additional","affiliation":[{"name":"Astellas Pharma B.V. Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Kaye","sequence":"additional","affiliation":[{"name":"RTI Health Solutions Waltham MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Perez\u2010Gutthann","sequence":"additional","affiliation":[{"name":"RTI Health Solutions Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Arana","sequence":"additional","affiliation":[{"name":"RTI Health Solutions Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,2,22]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)02243-4"},{"key":"e_1_2_8_3_1","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1080\/j.1600-0412.2000.079004298.x","article-title":"The prevalence and bothersomeness of lower urinary tract symptoms in women 40\u201060\u00a0years of age","volume":"79","author":"M\u00f8ller LA","year":"2000","journal-title":"Acta Obstet Gynecol Scand"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/02813430500362803"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.08.031"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.09.019"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-008-0600-9"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-014-9930-3"},{"key":"e_1_2_8_9_1","first-page":"798","article-title":"Data resource profile: the Danish National Prescription Registry","volume":"46","author":"Potteg\u00e5rd A","year":"2017","journal-title":"Int J Epidemiol"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/1403494810393562"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S91125"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/1403494811399958"},{"key":"e_1_2_8_13_1","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. International language for drug utilization research. December 16 2014.http:\/\/www.whocc.no\/. (last accessed on 10 March 2015)."},{"key":"e_1_2_8_14_1","unstructured":"Statistics Denmark. Website.2014.http:\/\/www.statbank.dk\/statbank5a\/default.asp?w=1600. (last accessed on 11 March 2014)."},{"issue":"3","key":"e_1_2_8_15_1","first-page":"S533","article-title":"Elevated bladder and prostate cancer rates following initiation of OAB medication: findings from a Danish Registry","volume":"25","author":"Hallas J","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"e_1_2_8_16_1","first-page":"S533","article-title":"Cancer risk in users of antimuscarinic drugs for overactive bladder: a cohort study in the Swedish National Registers","volume":"25","author":"Linder M","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4145"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1932"},{"key":"e_1_2_8_19_1","volume-title":"EU PAS Registration for Study Post\u2010Authorization Safety Program\u2014Validation of the Danish Data Resources for the Study of Cardiovascular and Neoplasm Events in Users of Treatments for Overactive Bladder","author":"ENCePP","year":"2016"},{"key":"e_1_2_8_20_1","unstructured":"Danish Health Board.The modernized cancer registry: method and quality [in Danish].2009.http:\/\/sundhedsdatastyrelsen.dk\/-\/media\/sds\/filer\/registre-og-services\/nationale-sundhedsregistre\/sygedomme-laegemidler-og-behandlinger\/cancerregisteret\/det-moderniserede-cancerregister.pdf?la=da. (last accessed on 15 November 2016)."}],"container-title":["Basic &amp; Clinical Pharmacology &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcpt.12965","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcpt.12965","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T13:01:29Z","timestamp":1695474089000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bcpt.12965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,22]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1111\/bcpt.12965"],"URL":"https:\/\/doi.org\/10.1111\/bcpt.12965","archive":["Portico"],"relation":{},"ISSN":["1742-7835","1742-7843"],"issn-type":[{"value":"1742-7835","type":"print"},{"value":"1742-7843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,22]]},"assertion":[{"value":"2017-07-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}